Bleakley Financial Group LLC Buys New Shares in NRx Pharmaceuticals, Inc. $NRXP

Bleakley Financial Group LLC bought a new stake in NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 117,204 shares of the company’s stock, valued at approximately $318,000. Bleakley Financial Group LLC owned about 0.40% of NRx Pharmaceuticals at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Sjbenen Advisory LLC acquired a new position in NRx Pharmaceuticals in the fourth quarter valued at $41,000. One Wealth Management Investment & Advisory Services LLC increased its stake in NRx Pharmaceuticals by 35.3% in the fourth quarter. One Wealth Management Investment & Advisory Services LLC now owns 37,873 shares of the company’s stock valued at $103,000 after purchasing an additional 9,882 shares during the last quarter. Global Retirement Partners LLC acquired a new position in NRx Pharmaceuticals in the fourth quarter valued at $107,000. Two Sigma Investments LP increased its stake in NRx Pharmaceuticals by 66.4% in the third quarter. Two Sigma Investments LP now owns 52,332 shares of the company’s stock valued at $173,000 after purchasing an additional 20,880 shares during the last quarter. Finally, Geode Capital Management LLC increased its stake in NRx Pharmaceuticals by 27.9% in the second quarter. Geode Capital Management LLC now owns 172,255 shares of the company’s stock valued at $562,000 after purchasing an additional 37,598 shares during the last quarter. 4.27% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on NRXP shares. BTIG Research restated a “buy” rating and set a $25.00 price target on shares of NRx Pharmaceuticals in a research note on Tuesday, March 24th. D. Boral Capital restated a “buy” rating and set a $34.00 price target on shares of NRx Pharmaceuticals in a research note on Tuesday, May 5th. Ascendiant Capital Markets upped their price target on NRx Pharmaceuticals from $48.00 to $49.00 and gave the stock a “buy” rating in a research note on Monday, April 27th. Zacks Research raised shares of NRx Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Monday, March 2nd. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of NRx Pharmaceuticals in a research note on Friday, May 8th. Four research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $38.25.

NRx Pharmaceuticals Stock Performance

Shares of NASDAQ:NRXP opened at $4.42 on Friday. The company has a market cap of $160.14 million, a P/E ratio of -4.06 and a beta of 2.02. NRx Pharmaceuticals, Inc. has a one year low of $1.62 and a one year high of $4.59. The business’s 50-day simple moving average is $2.78 and its 200 day simple moving average is $2.37.

NRx Pharmaceuticals (NASDAQ:NRXP) last announced its earnings results on Friday, May 15th. The company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.05) by $0.01. The company had revenue of $1.07 million for the quarter, compared to analysts’ expectations of $19.43 million. Analysts predict that NRx Pharmaceuticals, Inc. will post -0.3 earnings per share for the current year.

NRx Pharmaceuticals News Summary

Here are the key news stories impacting NRx Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright reiterated a Buy rating and a $45 price objective, and still sees long-term earnings growth for NRx Pharmaceuticals, with estimates remaining strongly positive in later years.
• Neutral Sentiment: The analyst continued to model a path to profitability over time, including estimated EPS of $0.67 for FY2027, $2.49 for FY2028, and $4.51 for FY2029, suggesting long-term upside potential if execution improves.
• Negative Sentiment: HC Wainwright cut its earnings estimates for multiple periods, including FY2026 to ($0.23) EPS from $0.13, FY2027 to $0.67 from $1.23, FY2028 to $2.49 from $3.18, FY2029 to $4.51 from $5.06, and FY2030 to $5.76 from $6.15, which likely weighs on sentiment.
• Negative Sentiment: Near-term quarterly forecasts were also reduced, including Q2 2026 to ($0.05), Q3 2026 to ($0.06), Q4 2026 to ($0.07), Q1 2027 to $0.00, Q2 2027 to $0.09, Q3 2027 to $0.21, and Q4 2027 to $0.36, signaling slower expected progress before profitability scales.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.